Medical management of abnormal uterine bleeding.
Abnormal uterine bleeding occurs secondary to a wide variety of functional and structural abnormalities. Although there is clearly a place for surgery, medical therapy has enormous potential for most women, especially those with dysfunctional uterine bleeding. To provide women with appropriate options for therapy, the clinician must be prepared to distinguish abnormal bleeding that is associated with ovulation from that which is anovulatory and to use appropriate ancillary tests to identify structural and endocrinologic anomalies or lifestyle factors that may explain the bleeding. In undertaking such an investigation, it is important for the clinician to be able to distinguish lesions that may be asymptomatic and unrelated to the bleeding from those that truly are the source of the problem. With this information, a rationally determined set of medical and, if appropriate, surgical therapeutic options may be presented to the woman. Among these medical treatment options are a number of treatment options that have not seen widespread use in North America but are inexpensive, effective, and well tolerated. It is clear that medical therapy is not for everyone. Women deserve the opportunity to relieve their symptoms with nonsurgical options.
Munro
M G
MG
Department of Obstetrics and Gynecology, School of Medicine, University of California, Los Angeles, USA.
D000728:Androgens / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D011372:Progestins / Q000008:administration & dosage / Q000627:therapeutic use; D014592:Uterine Hemorrhage / Q000188:drug therapy* / Q000209:etiology
D000728:Androgens; D000933:Antifibrinolytic Agents; D016861:Cyclooxygenase Inhibitors; D004967:Estrogens; D011372:Progestins; D007987:Gonadotropin-Releasing Hormone